CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
暂无分享,去创建一个
V. Golubovskaya | Lijun Wu | C. Chao | Lijun Wu | Vita Golubovskaya | Robert Berahovich | Hua Zhou | Shirley Xu | Hizkia Harto | Le Li | Cheng-Chi Chao | Mike Ming Mao | Shirley Xu | R. Berahovich | Hua Zhou | Hizkia Harto | Le Li
[1] Z. Eshhar,et al. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. , 2016, Annual review of pharmacology and toxicology.
[2] K. Odunsi,et al. The CD47 "don't eat me signal" is highly expressed in human ovarian cancer. , 2016, Gynecologic Oncology.
[3] Z. Eshhar,et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Katz,et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.
[5] D. Roberts,et al. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. , 2013, Matrix biology : journal of the International Society for Matrix Biology.
[6] H. Abken. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. , 2015, Immunotherapy.
[7] F. Bertucci,et al. CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction , 2011, Proceedings of the National Academy of Sciences.
[8] M. Hidalgo,et al. Inhibition of Cd47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanism Statement of Translational Relevance , 2022 .
[9] Daoud M. Meerzaman,et al. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer , 2016, Oncotarget.
[10] I. Weissman,et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.
[11] D. Roberts,et al. Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47* , 2010, The Journal of Biological Chemistry.
[12] Theresa A. Storm,et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors , 2017, Science Translational Medicine.
[13] M. Hidalgo,et al. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms , 2015, Clinical Cancer Research.
[14] J. Chen,et al. CD47: a potential immunotherapy target for eliminating cancer cells , 2016, Clinical and Translational Oncology.
[15] Lu Zhang,et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] Jens-Peter Volkmer,et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.
[17] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[18] V. Golubovskaya,et al. FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo. , 2017, Frontiers in Bioscience.
[19] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] I. Weissman,et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells , 2012, Leukemia.
[21] N. Hanna,et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery , 2016, Cancer Gene Therapy.
[22] M. Sadelain,et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity , 2014, Science Translational Medicine.
[23] F. Petrocca,et al. Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy , 2017, Cancers.
[24] V. Golubovskaya,et al. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy , 2016, Cancers.
[25] D. Gilham,et al. CAR T cells: driving the road from the laboratory to the clinic , 2014, Immunological reviews.
[26] Ash A. Alizadeh,et al. Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.
[27] Qiang Sun,et al. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer , 2016, Oncotarget.
[28] M. Maus. Designing CAR T cells for glioblastoma , 2015, Oncoimmunology.
[29] I. Weissman. How One Thing Led to Another. , 2016, Annual review of immunology.
[30] Jinquan Luo,et al. Leveraging SBDD in protein therapeutic development: antibody engineering. , 2012, Methods in molecular biology.
[31] Ash A. Alizadeh,et al. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.
[32] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[33] J. Bading,et al. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.